N-acetyl Semax Amidate is an acetylated form of the nootropic peptide Semax.
Developed to be pharmacokinetically more stable and increasingly resistant to enzymatic degradation form of Semax, it could have potential benefits for brain health and cognitive function. It is also an appropriate formulation of Semax and is believed to maintain the original’s neuroprotective and cognitive impacts.
What Is N-Acetyl Semax Amidate?
Russian researchers created the nootropic peptide Semax in the 1980s, and N-Acetyl Semax Amidate is considered to be an improved form. The seven-amino-acid sequence and structural similarity between Semax and N-Acetyl Semax Amidate are shared characteristics.
In this sequence, a portion of adrenocorticotropic hormone (ACTH, more precisely ACTH 4–7, or Met–Glu–His—Phe) is fused with a Pro–Gly–Pro extension at the C-terminus. Because of its unique formulation, Semax is considered to have the ability to cross the blood-brain barrier (BBB) and provide its nootropic impacts, potentially without inducing endocrine side effects.
Integrating acetic acid at the N-terminus and amidation at the C-terminus gives N-Acetyl Semax Amidate its distinctive N-terminal and C-terminal structures, which is believed to have additional action such as protecting the N- and C-termini from hydrolysis and degradation caused by leucine aminopeptidase.
Consequently, N-Acetyl Semax Amidate suggests greater stability in brain tissue. It is believed to have longer nootropic impacts after exposure, up to 30 minutes longer than Semax before it is destroyed in blood plasma.
The mechanisms and possible impacts of N-Acetyl Semax Amidate have not been well studied, and the data available mostly concern its pharmacokinetics, meaning how the body interacts with the substance once administered. Nevertheless, the peptide is expected to exert research potential similar to Semax. The pharmacodynamics of N-Acetyl Semax Amidate may be inferred from the existing scientific data on the processes of Semax.
Studies suggest that Semax may potentially increase neurotrophic factors that may promote neuronal survival and plasticity in the brain. These are said to include brain-derived neurotrophic factors (BDNF) and nerve growth factors (NGF). According to studies, exposure to Semax is hypothesized to raise BDNF levels by 40%.
Research indicates that the peptide may potentially induce a 100% increase in the brain’s tropomyosin receptor kinase B (TrkB) receptor expression. These receptors have the potential to mediate many of BDNF’s neuroprotective impacts.
One possible mechanism by which Semax may modulate hormone secretion, as well as stress, and other cognitive processes such as reward-motivated feedback, is via a potential increase in serotonin, dopamine, and enkephalin signaling.
Investigations purport that Semax could potentially have anti-ulcer impacts by regulating gastrointestinal blood flow, microcirculation, and vascular permeability, which is considered unrelated to its nootropic potential.
Further investigation is warranted as to whether N-Acetyl Semax Amidate may potentially have similar impacts. The peptide is considered to be only accessible as a research chemical in labs and classrooms.
N-Acetyl Semax Amidate Potential
As previously stated, N-Acetyl Semax Amidate may have little practical data. However, the altered peptide should have better pharmacokinetics and the same impacts as Semax.
Accordingly, to comprehend the possibilities of N-Acetyl Semax Amidate, the most recent data on Semax can be suummarized below.
N-Acetyl Semax Amidate and the Brain
N-Acetyl Semax Amidate may have neuroprotective potential in cases of stroke, nerve injury, and neurotoxic exposure conditions, as suggested by the Semax data that is currently accessible.
Increased BDNF levels and enhanced motor function were speculated in a study of 110 stroke research models who were routinely exposed to Semax for 10 days. According to another experiment, reducing inflammation appears to aid in the physiological recovery processes of stroke.
Reduction of pressure-driven nerve damage: One experimental study suggested that exposure to Semax may impact and mitigate glaucoma.
Neurotoxin protection: Animal models exposed to Semax while experiencing alcohol delirium suggested signs of being able to withstand potential neurotoxic action of ethanol exposure.
N-Acetyl Semax Amidate and Cognition
Researchers looking to undertake N-Acetyl Semax Amidate tests may want to peruse the substantial nootropic study on Semax first.
Fuurthermore, researchers have mostly looked at the peptide’s potential on cognitive load and brain activity.
Brain activity: Animal research models were studied to see how a 1% Semax solution compared to a control compound may have affected the Default Mode Network (DMN) in the brain. Semax appeared to significantly increase volume in the rostral subcomponent of the DMN, especially in the medial frontal cortex, as suggested by functional magnetic resonance imaging (fMRI) scans, which may indicate better information processing and episodic memory.
Cognitive decline: After prolonged stress response, research models exposed to Semax were evaluated to see whether it may have impacted cognitive function. The Semax group seemed to significantly outperform the control group, suggesting 71% accuracy on a later memory test.
N-Acetyl Semax Amidate and Ulcers
Investigations report that like Semax, N-Acetyl Semax Amidate may potentially have impacts outside the nervous system. According to some reports, peptic ulcers have been observed in animal models to heal faster upon exposure to Semax.
Russian researchers Ivanikov et al. speculated that Semax-exposed peptic ulcers may have healed three times faster than those of a control (30% vs. 90%). Researchers have hypothesized that by controlling blood flow and enhancing vascular function, Semax potentially may hasten the healing of peptic ulcers.
Although promising, the study above falls short of the rigorous standards required to be considered a noninferiority study. Keep in mind that the sequential approach may have a success record of over 94% in instances of Helicobacter pylori-induced peptic ulcers.
Scientists can buy research peptides of the highest quality for good prices through companies such as Biotech Peptides online.
References
[i] Kolomin, T., Shadrina, M., Slominsky, P., Limborska, S., & Myasoedov, N. (2013). A new generation of drugs: synthetic peptides based on natural regulatory peptides. Neuroscience and Medicine, 4(04), 223-252.
[ii] Khavinson, V., Ilina, A., Kraskovskaya, N., Linkova, N., Kolchina, N., Mironova, E., Erofeev, A., & Petukhov, M. (2021). Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer’s Disease. Pharmaceuticals (Basel, Switzerland), 14(6), 515.
[iii] Tsai S. J. (2007). Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. Medical hypotheses, 68(5), 1144–1146.
[iv] Shevchenko, K. V., Nagaev, I. Y., Andreeva, L. A., Shevchenko, V. P., & Myasoedov, N. F. (2019). Prospects for Intranasal Delivery of Neuropeptides to the Brain. Pharmaceutical Chemistry Journal, 53, 89-100.
[v] Markov, D. D., Dolotov, O. V., & Grivennikov, I. A. (2023). The Melanocortin System: A Promising Target for the Development of New Antidepressant Drugs. International journal of molecular sciences, 24(7), 6664.
[vi] Shevchenko, K. V., Nagaev, I. Y., Andreeva, L. A., Shevchenko, V. P., & Myasoedov, N. F. (2013). Stability of Semax acetyl to proteolysis in various biological media. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 449, 110–112.
[vii] Shadrina, M., Kolomin, T., Agapova, T., Agniullin, Y., Shram, S., Slominsky, P., Lymborska, S., & Myasoedov, N. (2010). Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. Journal of molecular neuroscience : MN, 41(1), 30–35.
[viii] Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Y., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain research, 1117(1), 54–60.
